Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Islander who wrote (3471)	3/15/2000 4:04:00 PM
From: Terry D.	Read Replies (1) \| Respond to of 3702

What phase III trials are you talking about? TUSTIN, Calif.--(BUSINESS WIRE)--March 15, 2000--Techniclone Corporation (NASDAQ:TCLN - news) today announced that the Company was issued U.S. Patent No. 6,036,955 on March 14, 2000 entitled ``Kits and Methods for the Specific Coagulation of Vasculature' by the U.S. Patent and Trademark Office. This patent covers particular methods of inducing molecules on tumor blood vessels for subsequent targeting and destruction and is a valuable addition to Techniclone's existing broad patent portfolio on its Vascular Targeting Agent (``VTA') technology. Dr. John Bonfiglio, Interim President, stated, ``We are very happy to have received another patent for Techiclone's proprietary VTA technology platform. This patent continues to strengthen our already strong patent position in this field. Clearly the value of Techniclone's patent position is evidencing itself through negotiations in progress and recently signed letters of intent with Oxigene, Inc. and SuperGen, Inc.' The VTA technology is Techniclone's proprietary therapeutic platform designed to specifically target tumor vasculature and subsequently destroy the tumor with various attached therapeutic agents. Although VEGF alone is being examined by many companies as a target for anti-angiogenisis agents, Techniclone holds the patents for attaching most therapeutic agents to VEGF for the purpose of targeting them to the tumor vasculature. Dr. Philip Thorpe, Professor of Pharmacology at the University of Texas, Southwestern Medical Center at Dallas, and the lead inventor of the VTA technology has shown proof of principle with this technology in several animal models, the results of which studies have been published in peer reviewed scientific journals, including Science in 1997.